Skip to main content

Table 1 Distribution of the prescription rates (×1000) of macrolides by country and the 10 most frequently assigned diagnostic categories in 2010

From: Sales of macrolides, lincosamides, streptogramins, and amoxicillin/clavulanate in the in- and outpatient setting in 10 European countries, 2007–2010

Prescription rates (%)

France

Germany

Italy

Netherlands

Poland

Spain

United Kingdom

Bronchitis

24.6 (28.0)

34.9 (36.4)

21.3 (17.3)

5.1 (11.4)

30.4 (24.7)

17.8 (10.5)

3.6 (4.3)

Pharyngitis

19.4 (22.1)

6.6 (6.9)

17.3 (14.0)

1.1 (2.4)

15.2 (12.3)

23.2 (13.7)

1.3 (1.5)

Gastrointestinal infections

7.9 (9.0)

1.4 (1.5)

10.4 (8.4)

0.6 (1.3)

1.7 (1.4)

41.9 (24.7)

1.1 (1.3)

Other upper respiratory tract infections

4.4 (5.0)

10.9 (11.4)

8.0 (6.5)

3.4 (7.6)

6.6 (5.3)

10.4 (6.1)

4.6 (5.4)

Tonsillitis

0.3 (0.3)

7.3 (7.6)

11.1 (9.0)

2.3 (5.1)

5.5 (4.5)

16.3 (9.6)

1.5 (1.8)

Sinusitis

3.7 (4.2)

8.2 (8.6)

2.6 (2.1)

6.3 (14.0)

9.9 (8.0)

5.1 (3.0)

1.3 (1.5)

Skin infections

1.0 (1.1)

1.6 (1.7)

7.8 (6.3)

6.9 (15.4)

2.7 (2.2)

2.1 (1.2)

10.8 (12.8)

Cold/influenza

6.8 (7.8)

1.1 (1.1)

1.2 (1.0)

0.6 (1.3)

3.2 (2.6)

5.9 (3.5)

0.7 (0.8)

Otitis media

0.8 (0.9)

2.7 (2.8)

3.4 (2.8)

1.9 (4.2)

4.2 (3.4)

6.9 (4.1)

1.5 (1.8)

Pneumonia

1.7 (1.9)

3.0 (3.1)

4.7 (3.8)

1.9 (4.2)

6.4 (5.2)

3.1 (1.8)

0.3 (0.4)

Total prescription rates macrolides by country

87.7

95.9

123.2

44.9

123.5

169.3

84.5